Literature DB >> 28100007

Race or genetic makeup for hepatitis C virus treatment decisions?

Thomas R O'Brien1, Shyam Kottilil2, Jordan J Feld3, Timothy R Morgan4, Ruth M Pfeiffer5.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28100007      PMCID： PMC5444941          DOI： 10.1002/hep.29057

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

1.  Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.

Authors:  K Rajender Reddy; Marc Bourlière; Mark Sulkowski; Masao Omata; Stefan Zeuzem; Jordan J Feld; Eric Lawitz; Patrick Marcellin; Tania M Welzel; Robert Hyland; Xiao Ding; Jenny Yang; Steven Knox; Phillip Pang; Hadas Dvory-Sobol; G Mani Subramanian; William Symonds; John G McHutchison; Alessandra Mangia; Edward Gane; Masashi Mizokami; Stanislas Pol; Nezam Afdhal
Journal:  Hepatology       Date:  2015-05-09       Impact factor: 17.425

2.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

3.  The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.

Authors:  Feng Su; Pamela K Green; Kristin Berry; George N Ioannou
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

4.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

5.  Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.

Authors:  Thomas R O'Brien; Krystle A Lang Kuhs; Ruth M Pfeiffer
Journal:  Open Forum Infect Dis       Date:  2014-12-13       Impact factor: 3.835
  5 in total
  7 in total

1.  Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Authors:  Thomas R O'Brien; Howard A Young; Raymond P Donnelly; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-04-17       Impact factor: 2.607

Review 2.  What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Authors:  Thomas R O'Brien; Sarah S Jackson
Journal:  J Interferon Cytokine Res       Date:  2019-06-04       Impact factor: 2.607

3.  IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling.

Authors:  Adeola A Obajemu; Nina Rao; Kari A Dilley; Joselin M Vargas; Faruk Sheikh; Raymond P Donnelly; Reed S Shabman; Eric G Meissner; Ludmila Prokunina-Olsson; Olusegun O Onabajo
Journal:  J Immunol       Date:  2017-10-25       Impact factor: 5.422

4.  The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.

Authors:  Jake R Morgan; Arthur Y Kim; Susanna Naggie; Benjamin P Linas
Journal:  Open Forum Infect Dis       Date:  2017-12-08       Impact factor: 4.423

Review 5.  Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals.

Authors:  Pil Soo Sung; Eui-Cheol Shin
Journal:  Int J Mol Sci       Date:  2020-04-08       Impact factor: 5.923

6.  Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials.

Authors:  Kimberly Struble; Kirk Chan-Tack; Karen Qi; Thamban Valappil; Sarah Connelly; Poonam Mishra; Dionne Price; Jeffrey Murray; Debra Birnkrant
Journal:  J Virus Erad       Date:  2019-09-18

7.  Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients.

Authors:  Seham Mahrous Zaki; Hanan Samir Ahmed; Monkez Motieh Yousif; Eman Mohamed Awad
Journal:  Trop Med Infect Dis       Date:  2022-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.